Physician profile
Li Fan
NPI 1730282658
$3,924.45
in general payments reported to CMS, 2019-2025
29 companies · $861 in 2025
The $861 reported for 2025 was more than what 89% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $178 · 2020: $126 · 2021: $793 · 2022: $718 · 2023: $676 · 2024: $573 · 2025: $861.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,044 · Education: $65.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,043.78 |
| Education | $65.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,170.63 | 2020-2025 | |
| Mayne Pharma Commercial LLC | $709.98 | 2021-2025 | |
| Evofem Biosciences, INC. | $241.31 | 2021-2025 | Solosec, Phexx, Phexxi |
| Astellas Pharma US INC | $205.92 | 2024 | Veozah |
| Aspira Women'S Health INC | $150.68 | 2022-2024 | Ova1 |
| Therapeuticsmd, INC. | $141.37 | 2019-2022 | |
| Avion Pharmaceuticals | $141.16 | 2021-2022 | |
| Intuitive Surgical, INC. | $132.18 | 2024 | |
| Exeltis, USA INC. | $114.32 | 2021-2023 | Slynd |
| Hologic Sales and Service, LLC | $113.76 | 2021-2025 | Aptima |
| Millicent US INC | $108.63 | 2024-2025 | Femlyv, Femring, Intrarosa |
| Corcept Therapeutics | $103.80 | 2025 | Korlym |
| Coopersurgical, INC. | $93.36 | 2021-2023 | Mara Console, Paragard T 380a |
| Roche Diagnostics Corporation | $72.85 | 2019-2021 | |
| Myovant Sciences INC. | $70.64 | 2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $55.49 | 2020 | |
| Sumitomo Pharma America, INC. | $50.34 | 2023-2024 | Myfembree |
| Shield Therapeutics INC | $33.97 | 2025 | |
| Lilly USA, LLC | $32.49 | 2025 | Zepbound |
| Pfizer INC. | $28.61 | 2019 | |
| Organon LLC | $26.35 | 2024 | |
| Agile Therapeutics, INC. | $23.90 | 2021 | |
| Novo Nordisk INC | $19.36 | 2023 | Wegovy |
| Zyla Life Sciences, INC. | $16.14 | 2020 | |
| Amag Pharmaceuticals, INC. | $14.69 | 2019 | |
| Mission Pharmacal Company | $13.65 | 2021 | |
| Daiichi Sankyo INC. | $13.37 | 2023 | Injectafer |
| Lupin INC. | $12.92 | 2019 | |
| Merck Sharp & Dohme LLC | $12.58 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Li Fan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.